It was in this environment in 1955 as a resident, late one night after finishing rounds on my very sick patients, that I picked up the latest issue of the Journal of the American Medical Association, at that time the most widely distributed medical journal in the world. I was struck by one of the lead articles. Three New York investigators2 reported that 27 of 35 consecutive stroke patients were dramatically improved after receiving cortisone. In 21, this improvement was seen within the first 24 hours. My patients were lying on the ward having difficulty swallowing and handling their secretions and often dying, and all I could do was support them. In the face of these very impressive statistics in consecutive patients, it seemed unethical not to go back to the wards and start cortisone immediately. But cortisone was and is a dangerous drug.
My first experience with the shortcomings of anecdotal studies had been two years before, in 1953. I had read a similar article describing dramatic improvement of consecutive patients with Huntington's disease treated with procainamide.3 As a senior medical student already converted to the true religion of the supreme organ system, I pleaded with my first-year resident, Dr William DeMyer, and my chief, Dr Alexander Ross, to prescribe it. They, with Dr Ralph Reitan, who at the time was developing the Halstead-Reitan battery which would become the basis for modern neuropsychology, were supportive. Their support was conditional upon my setting up, with their help, a well-designed experiment that would establish the effectiveness or lack of effectiveness of the therapy. I did. The study was completed and published in 1954 and to my disappointment showed no effect at all. 4 So again with the support of my staff, Dr Philip White, I designed a prospective, double-blind controlled study.5 Because we had observed many patients who completely recovered within minutes to hours, entry was delayed until 24 hours after the ictus. The results were sobering. Because of a higher mortality in the cortisone group, the study was aborted after entering only 36 patients. We could not prove the drug to be dangerous, but it was extremely unlikely that it would be beneficial. Later studies with less dangerous steroids6-11 followed the same pattern.
If one reviews the major controversies, they seldom are based on difference in science but rather on assumptions made on the basis of different anecdotal experience. Never trust a self-professed "honest man"! They lie to themselves. The investigator who considers the possibility that he might cheat will set up an experimen-tal design so tight that even if he tries to cheat, it will be impossible. The most reliable results come from the "dishonest" man! I vividly recall Dr Joseph Foley putting this into his usual picturesque words and completely damning an investigator with a single sentence. "He has never been surprised by any experiment he has ever performed."
In the words of Sir Frances Galton,12 the introducer of fingerprinting:
General impressions are never to be trusted. Despite the development of a number of sophisticated design and statistical techniques, all must include the same fundamentals. There must be a testable hypothesis; an experiment designed to exclude bias; and the probability of the results occurring by chance must be so low as to be unacceptable. For clinical trials, this requires that the study is prospective, the treatment determined randomly and double-blinded, and the numbers large enough to avoid type II error. Regardless of how sophisticated the statistical tests are, they must be determined at the onset of the study. By changing statistics and looking at data many times, it is almost certainly possible to obtain any result one would wish.
One of the most important innovations is metaanalysis. Later, when I disagree with some of the conclusions said to be based on meta-analysis, it will not be a criticism of the tool but of the inappropriate extrapolation of conclusions. This is an extremely powerful technique based on pooling data from a large number of similar studies. This large pool of data enables researchers to draw highly significant conclusions because of the increase in numbers and to avoid the systemic bias of drawing conclusions from just a few well-known studies selected from dozens of related studies. 13 The Antiplatelet Trialists stressed that patients in one trial should never be directly compared with those in another. Not only might the patients have been different but so too might the treatments, duration of treatment, quality of follow-up, and end-point definitions. We should compare only like with like within one trial and not assume that the sizes of any risk reductions in different trials must be similar. The scientific requirements for meta-analysis are the same as for individual studies just described14 and at best can answer only the hypothesis proposed in the original studies.
The method of analysis commonly used in stroke studies is that of Mantel-Haenszel-Peto."3 Its brilliance is reflected in its simplicity. In summary, 0 refers to the observed end points in the treatment groups and E to the expected end points. The observed minus the ex- In the 1950s a number of anecdotal reports suggested that patients presenting with transient ischemic attacks (TIAs) and mild stroke were favorably affected by acute treatment with heparin and long-term treatment with warfarin. Although this was one of the first areas in which properly designed studies were initiated, the controversies are still raging. For TIAs, only four studies have been reported16-19; because these were so numerically underpowered (with a total of only 93 treated patients and 85 controls), it is not surprising that, except for a trend toward increased mortality in the treated patients, no statistical differences were noted in any individual study or in aggregate. These numbers are far too low to exclude type II error.
As recently as a month ago, I was shocked to hear an internationally known investigator state that as long as randomization is successful, blinding is not necessary. As an example of how bias might affect even a randomized, well-designed study that is not blinded, I would like to share an anecdote with you. In the 1960s we were interviewing a non-neurologist for a position at Indiana University who came from one of the centers participating in one of the controlled studies of anticoagulation. I asked why he thought this center had excellent results in its randomized pilot study and such poor results when it entered a multicenter blinded study. The answer was not surprising. The patients in the pilot studies who were assigned to the warfarin group were monitored very closely, seen immediately for any complaint, and followed up frequently with all risk factors treated vigorously. Those assigned to the placebo group were asked to call or return if they had any events and were sent back to their referring physicians. Obviously, the study was biased not by the differences in the use of anticoagulation but by the better general treatment of risk factors.
The entire subject of anticoagulation in stroke prevention must be reopened. In this country the dose of warfarin has been based on a prothrombin time of 2.0 to 3.0 INR units, but the North American thromboplastin used is not equivalent to that used internationally. 20 We may have been poisoning a large number of patients. A prothrombin time of 2 to 3 times normal would exceed 4.0 INR.
The good news is that at long last several studies are in progress that are expected to give definitive answers within the next few years.21 Acute therapy with heparinoids is being investigated in a multicenter trial under the leadership of Dr Harold Adams. Another, headed by Dr J.P. Mohr, is investigating the value of long-term, low-dose warfarin in patients with stroke.
Another bright spot is the use of anticoagulants in chronic atrial fibrillation. Four studies (Copenhagen,22
Boston,23 Stroke Prevention in Atrial Fibrillation [SPAF] ,2425 and Veterans Affairs26) have reported a marked reduction in outcome events in patients on low-intensity anticoagulation with warfarin. Unfortunately, they were not double-blinded; however, as the design is rigid and all are going the same way, we would hope that they are valid. The participants in each of these studies agree on the warfarin results but disagree whether aspirin is effective.
In the SPAF Study, 325 mg/d aspirin was associated with significant relative risk reduction.24,25 The Copenhagen22 and the Boston23 trials reported no aspirin effect. In the Boston study, aspirin was not randomly assigned but taken at the discretion of the patient; in the Copenhagen study, the dose was only 75 mg/d and the patients were much older than those in SPAF. Therefore, these studies are not comparable. The SPAF study is continuing with the aspirin and warfarin arms, and this controversy should be settled soon. 27 The study has been concluded and the final results will soon be available.
In 30 -day mortality, whereas the National rates are based on deaths that occur in the hospital. The decrease in mortality rate appears to be across the board in all groups. The decrease was uniformly present in hospitals large and small, urban and rural, teaching and nonteaching, and for profit and not for profit. Although the trend is good, the death rate of 2.3% is still far too high, and the combined mortality and stroke rate still must range from 5% to 11% for all Medicare patients. This must be corrected, as the benefit reported in the NASCET and ECST studies depended on a much lower complication rate from the participating surgeons. These studies establish that lower rates are possible in the hands of selected surgeons.
Aspirin has been known to be effective in stroke prevention for some time. At least nine studies of aspirin for patients with TIAs or minor stroke were reported before 1990.54-65 In all but two, a statistical benefit was established.!62 The value of aspirin should no longer be a controversy, but several issues are still debated, including gender differences, benefit of adding dipyridamole, proper dose, and the risk-to-benefit ratio compared with that of ticlopidine.
Women did not appear to benefit from aspirin in the Canadian study56 and the United Kingdom Study. 64 In 1980, I reviewed the controls in prospective studies in which events were related to gender.66 In the studies of aspirin, the event rate in treated men only approached that of untreated women. It was postulated that the lack of an observed effect on women was probably because the event rates are comparatively low in women; thus, an effect might not become apparent during a few years of follow-up of a small number of women who were at relatively low risk. Aspirin was effective in women with TIA and mild stroke in the European Stroke Prevention Study63 and the French AICLA Study.58'60 I cannot resist commenting on the European study results because they so closely reflected what was predicted. The life-table analysis indicated that results in treated men were quite similar to those in untreated women, but both do better on aspirin.
Aspirin doses as low as 30 mg/d will block cyclooxygenase and the release of thromboxane A2 in platelets and have very little or no effect on the prostacyclin system in the endothelium. Therefore, low dose might induce a desirable combination effect. Also, in theory, if the prostacyclin function in the endothelium could be enhanced by a drug like dipyridamole, the patient might additionally benefit.
Dipyridamole combined with aspirin has been compared with aspirin alone in three studies, two French studies58-60 and the American-Canadian Co-Operative Study Group.67 In none was an additional benefit shown by adding dipyridamole to aspirin. Although the controversy is said to continue, these studies should have settled the issue.
The widespread acceptance of low-dose aspirin may have been enhanced by conclusions drawn from metaanalysis.'3 The Antiplatelet Trialists performed a metaanalysis of clinical trials of TIA, stroke, surgical trials, myocardial infarction, and unstable angina. They also used a heterogeneous group of end points (definite stroke, probable or definite nonfatal myocardial infarction, and all deaths that might have been vascular or hemorrhagic). Therefore, the hypothesis could not have been the same for each study. In this mixed group, 900 to 1500 mg/d was associated with a 23% reduction in end points and 300 to 325 mg/d with a 24% reduction. But none of the lower dose studies were of cerebrovascular disease. In this report the studies of cerebrovascular disease all used 975 mg/d or more.
In the only direct comparison of 300 versus 1200 mg/d, the United Kingdom Study, 2435 patients were entered with TIA or minor stroke.f6465 They were randomized to 300 or 1200 mg/d aspirin or to placebo. Neither aspirin dose alone was significantly better than placebo. Data reported in the paper indicated a slight trend for a better response to 1200 mg than to 300 mg. The percentage differences were not significant but were as high as 8 Because the reductions in end points in the UK-TIA Study and the SALT study are modest (15%, 18%, or less), Dr Barnett and I performed independent analyses comparing these results to those of studies of TIA and mild stroke that showed a benefit using higher doses of aspirin.70 The same calculations were performed for each study using the actual numbers published in the original papers. In only one study was this figure different from that published by the authors (13% versus 15%), which may reflect a slightly different type of analysis.
The reduction in stroke and death ranged from only 3% to 18% in the SALT and UK-TIA studies compared with 25% to 42% in the others. Only three studies reported stroke, myocardial infarction, or vascular death as end points. In the SALT68 and UK-TIA64,65 studies, reductions were 17% and 13%, respectively, compared with 40% in the Parisian58-60 study. This is not the way science should be conducted, but this mini-meta-analysis raises the possibility that 325 mg or less may not be as effective as 975 mg or more.
After carotid endarterectomy, Boysen et a171 compared 50 to 100 mg/d to placebo. Despite dose titration to the point of a platelet effect, stroke and death were not reduced. Studies using higher doses have shown an effect. Kretschmer et a172 observed in a retrospective study a marked reduction in mortality in patients receiving 1500 mg/d aspirin. Following this, their prospective study73 reported a statistically significant decrease in death in only 68 patients. In the surgical arm of the United States aspirin study by Fields et al,55 those who received 1300 mg/d aspirin had significantly fewer strokes and stroke deaths at 24 months of follow-up than those on placebo.
In the NASCET study, Barnett observed that at 18 months, ipsilateral stroke had occurred in 11% of those taking 325 mg/d aspirin, in 10% of those taking 650 mg/d, and in only 4% of those taking 1300 mg/d.70 These data must be interpreted with caution because the study was not designed to test the effect of aspirin. Nevertheless, if the dose of aspirin had been a primary end point, the numbers were high enough and the differences great enough for this to be statistically significant.
The Physicians' Health Study74'75 may give some insight into the appropriateness of extrapolating mixed end points for heart and brain and drawing conclusions concerning a subgroup with cerebrovascular disease. This is in itself a megastudy. In it, 22 071 male physicians received 325 mg aspirin or placebo every other day for 5 years. If the mechanisms and the effects are the same, one would expect that if enough events occurred, the same trends should have been seen for both heart and brain. Because of a very significant decrease in myocardial infarction in the aspirin group, this study was terminated early. Of Ticlopidine has been established as the first platelet antiaggregant since aspirin to effectively reduce further stroke and death for patients with TIA, mild stroke, and moderate stroke. The Ticlopidine Aspirin Stroke Study (TASS),86 a study of 3069 patients with TIA and mild stroke, compared ticlopidine (500 mg/day) with aspirin (1300 mg/day). The ticlopidine group had a 21% decrease in all types of stroke at 3 years and a 47% risk reduction at 1 year. The Canadian American Ticlopidine Study (CATS)87 demonstrated superiority over placebo in patients with moderate-to-severe stroke.
There should be no controversy over the benefit of ticlopidine. The controversy here is not concerning effectiveness but rather the interpretation of risk-benefit ratio. Almost 1% of patients experienced a serious neutropenia within 90 days. Some interpret this as a contraindication of its use except in special circumstances. Others use it with little reservation because in every case the neutropenia occurs within 3 months, and recovery occurs rapidly when the drug is stopped.
This review of current and past controversies was not meant to be comprehensive. I hope it has been of some value in making the point that we must never vary from our rigid scientific principles. We must draw conclusions only about the hypotheses tested and not extrapolate and make assumptions that are not warranted by the data. If we don't, we will continue to have more and more unsolvable controversies.
Unfortunately, many good studies have been and are going to be negative and not turn out the way we wish. As I am thinking about this as we approach the end of this 40-year journey and wondering if it is all worth it, a paraphrase of the words of Edna St. Vincent Millay88 keeps echoing through my mind:
My candle burns at both ends. It will not last the night. But, ah, my foes and, oh, my friends It gives a lovely light.
